Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The Company has discovered and developed small molecule, Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein XPO1. The Company�s drug candidate, Selinexor (KPT-330), is an XPO1 inhibitor, evaluated in multiple open-label Phase 1 clinical trials in patients with heavily pretreated relapsed or refractory hematological and solid tumor malignancies. As of September 20, 2013, the Company had administered Selinexor to over 170 patients in these trials.